

# VITILIGO SUPPORT UK

England & Wales - Charity number 1170557

## Details

---

**Status** Registered

**Legal form** CIO

**Registered** 2016-12-05

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** 36 Avondale Avenue  
Esher  
KT10 0DA

**Phone** 07976230802

**Email** [info@vitiligosupport.org.uk](mailto:info@vitiligosupport.org.uk)

**Website** [www.vitiligosupport.org.uk](http://www.vitiligosupport.org.uk)

## Activities

---

**Objects:** TO PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH OF SUFFERERS OF VITILIGO IN ENGLAND AND WALES BY THE PROVISION OF SUPPORT, EDUCATION AND PRACTICAL ADVICETO ADVANCE THE EDUCATION OF THE GENERAL PUBLIC IN ALL AREAS RELATING TO VITILIGO

**Activities:** Providing information, support and advocacy to people in the United Kingdom in relation to their vitiligo, including disseminating research, advising on accessing treatments and the efficacy of treatments when supported by research, replying to messages, arranging MeetUps around the UK and in London and providing newsletters and information sheets to advise on key areas of vitiligo treatment

## Classification

---

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups, The General Public/mankind

## Geography

---

- Throughout England And Wales

## Finances

Period end	Income	Expenditure	Assets	Employees
2025-04-01	£1,545	£828	-	-
2024-04-01	£355	£45	-	-
2023-04-01	£1,286	£101	-	-
2022-04-01	£84	£84	-	-
2021-04-01	£84	£84	-	-

## Trustees

Name	Role	Appointed
<b>EMMA RUSH</b>	Chair	2016-07-01
Dr Catherine Dale		2017-03-01
PETER DAVID RUSH		2016-07-01

**VITILIGO SUPPORT UK**

England & Wales - Charity number 1170557

---

# Accounts

---

ANNUAL REPORT

2024-

2025

Vitiligo Support UK Reg: 1170557

# **Vitiligo Support UK**



*Providing support & advocacy  
to all with vitiligo*

# Table Of Contents

---

<b>Introduction</b>	<b>1-4</b>	<b>Conferences, presentations, &amp; media</b>	<b>13-16</b>
<b>Message from CEO</b>	<b>5-8</b>	<b>Public Advocacy: NICE &amp; ruxolitinib</b>	<b>17-19</b>
<b>Financial Review</b>	<b>9-10</b>	<b>Thank You</b>	<b>20-21</b>
<b>Research Projects &amp; Charity Collaborations</b>	<b>11-12</b>		

# **Charity Status, Legal & Financial Overview**

**Vitiligo Support UK is a Charitable  
Incorporated Organisation**

**Founded:** 05 December 2016

**Charity Number:** 1170557 (England & Wales)

**Website:** [www.vitiligosupport.uk](http://www.vitiligosupport.uk)

**Address for Correspondence:** 36 Avondale  
Avenue, Esher, KT10 0DA.

**Bankers:** Virgin Money, 15-17 Castle Street ,  
Kingston upon Thames , KT1 1ST.

# 2024-2025 Annual Report



## Supporting patients...

## Providing health advocacy

Welcome to our Annual Report, a showcase of our achievements, progress, & commitment to patients with vitiligo, their families & friends throughout the year.

# 2024-2025 Annual Report



Dear Supporters & Followers,

I am delighted to present our Annual Report, which details all we have achieved in our ongoing & tireless support of vitiligo patients in England & Wales. In addition, we have also worked internationally through participation in research projects.

We operate on very low outgoings compared to other charities in this field, & are very grateful for the contributions made to the charity by the general public over the past year.

## 2024-2025 Annual Report

The generosity of our members enabled our attendance at the BAD Annual Conference & our continued representation of vitiligo & vitiligo patients as worthy of treatment & our disease as an important autoimmune disease with risk of comorbidities we are concerned are being missed in primary care.

We have no paid employees so all of the work described in this annual report is provided voluntarily by our CEO & volunteers.

The past year has been one of significant work & advocacy provided in support of the first new & specifically for vitiligo topical treatment, ruxolitinib. Currently, in England & Wales, patients are routinely given topical steroids to begin their treatment pathway, which are of limited efficacy.

# 2024-2025 Annual Report



Our representation of vitiligo patients included in-person advocacy at NICE committee meetings, preparation & submission of written documentation in support of ruxolitinib as a treatment & canvassing the support in written form of a significant number of vitiligo patients through our membership.

Thank you for your support, & we look forward to another year of action & advocacy for vitiligo patients.

Emma Rush, CEO, Vitiligo Support UK



# Financial Review

**Review of the charity's financial position at the end of the period (Para 1.21):** The charity maintained its stable financial position in this period.

**Statement explaining the policy for holding reserves stating why they are held (Para 1.22):**

No material reserves are held due to the charity's conservative management.

**Amount of reserves held (Para 1.22):** See above.

**Reasons for holding zero reserves (Para 1.22):**

See above.

**Explanation of any uncertainties about the charity continuing as a going concern (Para 1.23):**

None.

# Financial Review

## **Additional information (optional):**

You may choose to include further statements where relevant about:

**The charity's principal sources of funds (including any fundraising) (Para 1.47):**

Donations from the general public.

.

# Research projects & charity collaborations

In the autumn of 2024, we were invited by Dr Eleftheriadou to be a patient representative in the VIRTUAL UK project: VItiligo RegisTry for adUlts & children in the UK.

This is a multi-centre, prospective, observational clinical registry of paediatric & adult patients with vitiligo on phototherapy, or novel topical/systemic immune-modulatory therapies.

Obtaining registry data allows researchers to gain a better understanding of how vitiligo “behaves” under treatment, including examination of the high risk of relapse following interventions.

# **Research projects & charity collaborations**

We were also amongst a group of charities invited by Professor Diana Harcourt of the Centre for Appearance Research at the University of West of England to help them develop a new website for CAR's visible difference resources/materials.

We have previously participated in two research projects with CAR, one of which informs the acceptance & commitment therapy intervention on the website.

<https://visibledifferencesupporthub.com/>

# Conferences, presentations, & media

On 23 September 2024, our CEO, Emma Rush, appeared alongside Dr Viktoria Eleftheriadou & the actress, Georgia May Foote. The appearance followed our advocacy as a charity during the NICE appraisal process for Vitiligo Support UK. The slot included discussion of the impact of vitiligo, current treatments & the hope generated by the prospect of a new specific treatment for our skin disease.



Image copyright © 2026 BBC

## **Conferences, presentations, & media**

In July 2024, as the patient representative on the British Association of Dermatologists' Conference Organising Committee, our CEO attended the Annual Conference in Manchester.

This led to building relationships with fellow patient support charities in the dermatology field & gave opportunities for networking (within the APBI Code of Practice).

We were also able to attend the presentation by Incyte on their new topical treatment for vitiligo, ruxolitinib, & invited to share the patient perspective on the desperate need for treatment amongst a patient group that experiences a significant psychological impact of their disease.

# Conferences, presentations, & media


In addition, we were pleased to attend the poster presentation by Dr Eleftheriadou on vitiligo & again, we were allowed to present the patient perspective to those who attended.



# Conferences, presentations, & media

In February 2025, we continued to build our relationship with the British Dermatological Nursing Group by writing an article on how vitiligo patients feel invisible to the healthcare profession.

We then contributed to their podcast series, recording a podcast in April 2025.



The image shows a screenshot of a podcast player interface. At the top, the title "Vitiligo Support UK" is displayed in blue text, with a sub-line "Posted on 24th June 2025 by Susan Maguire". Below this is a podcast player for "BDNG Podcasts" with the episode title "Vitiligo Support UK". The player includes a play button, volume control, and a progress bar showing "00:00 / 00:34:47". To the left of the player is a logo for "BDNG PODCASTS" featuring a stylized flower and headphones. Below the player, there are links for "Download file" and "Play in new window", along with the text "Duration: 00:34:47 | Recorded on 24th June 2025". At the bottom, a description reads: "Emma Rush, CEO, Vitiligo Support UK joins the podcast. More information at <https://www.vitiligosupport.uk/>".

## **Public Advocacy: NICE & ruxolitinib**

Currently, only two topical & unlicensed treatments are available to vitiligo patients in primary care & access to hospital-based phototherapy as the third line of treatment depends on waiting lists in the patient's area & ability to commit to a lengthy course of treatment.

This has led to our overriding aim as a charity, to help patients gain access to treatment in a healthcare environment that still shows considerable resistance to treating our disease appropriately.

Currently, the only treatments available are standard ones that are prescribed across a number of inflammatory skin diseases, & are not specifically licensed for vitiligo.

The drug company, Incyte, brought ruxolitinib to NICE for approval for prescription in the NHS in 2024.

# Public Advocacy: NICE & ruxolitinib

At the Committee Meeting that was called by NICE to appraise ruxolitinib for prescription within the NHS, we represented the charity, sharing patients' experience & advocating for our skin disease to be granted access to the first treatment ever specifically researched & designed for vitiligo.

We were supported by a patient from our membership who gave a moving & powerful account of living with vitiligo as a person with skin of colour.

We were also privileged to have Dr Jonathan Batchelor (lead investigator on the HI-Light trial), Dr John Ferguson (lead of the Vitiligo Centre at Guy's hospital) & Dr Antony Bewley (co-chair of Psychodermatology UK) represent the charity as clinicians.

## **Public Advocacy: NICE & ruxolitinib**

Unfortunately, NICE turned down Incyte's application, & we subsequently went to appeal, represented again by our clinical team & by our CEO.

Throughout the process, we fully engaged with NICE & its procedures, delivering on time & providing extensive written support for the prescription of ruxolitinib together with patient testimony to demonstrate the real & significant impact of the disease.

The appeal was also turned down, & we instituted a campaign of writing to local MPs which generated several leads & some engagement.

We still are waiting for recognition of the impact of vitiligo as an auto-immune disease with a considerable psychological burden & comorbidities.



We are enormously grateful to all our members who donated to the charity over this & who gave enormous support to our cause, in particular during our first appraisal meeting & the appeal meeting with NICE.

As a charity, we understand that vitiligo can impact you in many different ways, but we are always concerned to give a voice to those who have become invisible to our healthcare system.

We advocate passionately for vitiligo patients in many different fora & look forward to going on representing people with vitiligo in the future



We extend particular thanks to the following contributors to the work we complete for vitiligo patients:

Dr Jonathan Batchelor  
Dr Anthony Bewley  
Dr Viktoria Eleftheriadou  
Dr John Ferguson  
Dr Tessa McPherson  
Dr Tamara Griffiths  
Dr Kate Dale

Vivien Ambrose  
Claudia Money  
Peter Rush  
Pav Korpál

And all of the community in our closed Facebook Group.

ANNUAL REPORT

2024-

2025



[www.vitigosupport.uk](http://www.vitigosupport.uk)



[info@vitigosupport.uk](mailto:info@vitigosupport.uk)



[www.facebook.com/groups/VitigoSupportUK](https://www.facebook.com/groups/VitigoSupportUK)



## Receipts and payments accounts

For the period from	03-Apr-24	To	02-Apr-25
---------------------	-----------	----	-----------

### Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
<b>A1 Receipts</b>					
Donations	1,545	-	-	1,545	1,084
Grant	-	-	-	-	-
Interest Received	-	-	-	-	202
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total (Gross income for AR)</b>	<b>1,545</b>	<b>-</b>	<b>-</b>	<b>1,545</b>	<b>1,286</b>
<b>A2 Asset and investment sales, (see table).</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total receipts</b>	<b>1,545</b>	<b>-</b>	<b>-</b>	<b>1,545</b>	<b>1,286</b>
<b>A3 Payments</b>					
Insurance	110	-	-	110	101
JustGiving fee	216	-	-	216	-
Conference Expenses: BAD July 2024	334	-	-	334	-
Website Hosting	168	-	-	168	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>828</b>	<b>-</b>	<b>-</b>	<b>828</b>	<b>101</b>
<b>A4 Asset and investment purchases, (see table)</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total payments</b>	<b>828</b>	<b>-</b>	<b>-</b>	<b>828</b>	<b>101</b>
<b>Net of receipts/(payments)</b>	<b>717</b>	<b>-</b>	<b>-</b>	<b>717</b>	<b>1,185</b>
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	1,476	-	-	1,476	-
<b>Cash funds this year end</b>	<b>2,193</b>	<b>-</b>	<b>-</b>	<b>2,193</b>	<b>1,185</b>

### Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
<b>B1 Cash funds</b>	Cash at Bank	2,193	-	-
CCXX R1 accounts (SS)	1	-	-	\$1/01/2026 -

	-	-	-
<b>Total cash funds</b>	<b>2,193</b>	<b>-</b>	<b>-</b>
(agree balances with receipts and payments account(s))	OK	OK	OK

		Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
<b>B2 Other monetary assets</b>	<b>Details</b>	-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-

		Fund to which asset belongs	Cost (optional)	Current value (optional)
<b>B3 Investment assets</b>	<b>Details</b>		-	-
			-	-
			-	-
			-	-
			-	-

		Fund to which asset belongs	Cost (optional)	Current value (optional)
<b>B4 Assets retained for the charity's own use</b>	<b>Details</b>		-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-

		Fund to which liability relates	Amount due (optional)	When due (optional)
<b>B5 Liabilities</b>	<b>Details</b>		-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees	Signature	Print Name	Date of approval

**VITILIGO SUPPORT UK**

England & Wales - Charity number 1170557

---

# Accounts

---



## Trustees' Annual Report for the period

From **02/04/2023** Period start date To **01/04/2024**  
Period end date

Charity name: **Vitiligo Support UK**

Charity registration number: **1170557**

## Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To promote and protect the physical and mental health of sufferers of vitiligo in England and Wales by the provision of support, education and practical advice and to advance the education of the public in all areas relating to vitiligo
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	
<p>We are a small charity and have been in existence for less than a decade, unlike other charities in this sphere of activity.</p> <p>However, we devote considerable time, skill and energy to fulfilling our charitable objectives, and have significantly proved our worth and confirmed our reputation for the thoughtful and committed care of people with vitiligo in this period in the following ways.</p> <p>We have used social media including our new website to signpost services and information. We used it in a particularly efficacious way in garnering patient statements of impact in support of our submission to NICE (see below).</p> <p>Providing advocacy for patients with vitiligo via membership of committees and working groups within the British Association of Dermatologists (BAD).</p> <p>Leading as patient representative on the Education Sub-Committee at the BAD and as patient representative on the Conference Sub-Committee.</p> <p>Answering queries relating to access to treatment and providing a Guide to talking to your GP about Treatment that details the steps for patients to take to push back against dismissal by clinicians in primary care as having “merely” a cosmetic disease.</p> <p>Providing extensive individual support to our members and answering a significant number of one-to-one queries raised with us.</p>		

In 2023/2024, we prepared a submission to the National Institute of Health and Care Excellence in support of Incyte Biosciences UK's application for approval of the novel topical treatment, ruxolitinib, for prescription on the NHS.

We were punctilious in submitting on time, following procedure and providing an outstanding response as a patient support organisation explaining the pressing need for a licensed novel treatment for our disease.

This also involved canvassing the very moving testimonies of our members as to the psychological, physical and cultural impact on them of their vitiligo. People gave very generously of their time and their personal accounts of this disease, and we are enormously grateful for their help. In the appraisal meeting, the Committee Chair made reference to these submissions, indicating that they had moved the members of the committee. The decision made was negative, but we continue to work tirelessly for its ultimate approval by participating in the appeal process, following the NICE requirements and ensuring that we were timely in our responses.

In our attendance at the appraisal meeting, we gave evidence of the impact of this disease. We were very pleased to be supported in this by the clinician Dr Jonathan Batchelor, who ran the HI-Light trial at Nottingham University in 2012 and by our patient expert, who was selected to appear.

This formed a major part of the work undertaken in the public forum for vitiligo patients.

However, we continue to hold to the objective that patients require support in their quest for treatment.

Social media exposure of the disease, even its monetization, has increased but this still does not help the patient in their daily lives.

It is our goal to help people gain treatment, and the best and most appropriate course of treatment for their skin disease. We close with a quote from a patient bearing witness to the power of information in gaining treatment, "Had my dermatology appointment today, and just wanted to say thanks to Emma Rush. I let the doctor have her say and she basically had told me they can't do nothing...then I told her, you can do something and told her about this group and Emma, also mentioned the nice guidelines and they should offer me some treatment... she changed her tune and is referring me to have phototherapy and make sure I get any new treatment available...which I know will be a long wait for this, but asked if they could give me some creams to try while I'm waiting, she prescribed me some topical cream.

I honestly felt so good walking out this appointment, as I feel I stood my ground and was not walking out without any treatment 😊 first time ever I felt good walking out of a dermatology appointment. Thank you so much Emma."

Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	We have had regard to the guidance issued by the Charity Commission in respect of public benefit.
--	-----------	---

**Additional information (optional)**

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	

Policy on social investment including program related investment	Para 1.38	
Contribution made by volunteers	Para 1.38	
Other		

## Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p>As a charity, we have provided extensive support to our membership in navigating access to dermatology.</p> <p>This remains a significant challenge for patients, and we are in the process of joining research conducted in Scotland relating to moving the referral to phototherapy into primary care, research that may be overtaken by government policy.</p> <p>The waiting lists in dermatology are unacceptably long, and the concern remains that vitiligo patients are triaged out of secondary care in favour of other inflammatory skin conditions.</p> <p>Our Guide to talking to your GP about your vitiligo, based on the information provided by the Primary Care Dermatology Society, has continued to be an extremely useful tool for patients to open conversations and push for treatment in primary care and referral to secondary care where appropriate.</p> <p>We also continue to promote the BAD Guidelines for managing patients with vitiligo as a means for patients to gain access to treatment. It would be great if this became standardised across patient support bodies as they provide a significantly powerful tool for patients to advocate for their treatment.</p> <p>We spoke at the NSS Photonet conference again, advising Scottish clinicians of the importance of recognising that vitiligo can be treated and is most successfully treated via narrowband uvb.</p>

**Additional information (optional)**

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

## Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	The charity maintained its stable financial position in this period.
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	No material reserves are held due to the charity's conservative management.
Amount of reserves held	Para 1.22	See above.
Reasons for holding zero reserves	Para 1.22	See above.
Details of fund materially in deficit	Para 1.24	See above.
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	None.

### Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	Donations from the general public.
Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	
Other		

## Structure, Governance and Management

Description of charity's trusts:		
Type of governing document (trust deed, royal charter)	Para 1.25	CIO Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	Charitable Incorporated Organisation
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Trustees are appointed by the existing trustees, following the provisions of the constitution.

### Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

### Reference and Administrative details

Charity name	Vitiligo Support UK
Other name the charity uses	
Registered charity number	1170557
Charity's principal address	36 Avondale Avenue, Esher, Surrey KT10 0DA

**Names of the charity trustees who manage the charity**

	<b>Trustee name</b>	<b>Office (if any)</b>	<b>Dates acted if not for whole year</b>	<b>Name of person (or body) entitled to appoint trustee (if any)</b>
1	Emma Rush	Chair of Trustees		
2	Peter Rush			
3	Kate Burnside			
4	Sara Day			
5	Joanna Jackson			
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

**Corporate trustees – names of the directors at the date the report was approved**

<b>Director name</b>		

**Name of trustees holding title to property belonging to the charity**

<b>Trustee name</b>	<b>Dates acted if not for whole year</b>	

## Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	

### Additional information (optional)

#### Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
-----------------	------	---------


#### Name of chief executive or names of senior staff members (Optional information)

--

## Exemptions from disclosure

Reason for non-disclosure of key personnel details

None
------

## Other optional information

--

## Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

<b>Signature(s)</b>		
<b>Full name(s)</b>		
<b>Position (eg Secretary, Chair, etc)</b>		
<b>Date</b>		



## Receipts and payments accounts

CC16a

For the period from	3-Apr-23	To	2-Apr-24
---------------------	----------	----	----------

### Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
<b>A1 Receipts</b>	-				
Donations	355	-	-	355	1,084
Grant	-	-	-	-	-
Interest Received	-	-	-	-	202
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total(Gross income for AR)</b>	<b>355</b>	<b>-</b>	<b>-</b>	<b>355</b>	<b>1,286</b>
<b>A2 Asset and investment sales, (see table).</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total receipts</b>	<b>355</b>	<b>-</b>	<b>-</b>	<b>355</b>	<b>1,286</b>
<b>A3 Payments</b>					
Insurance	45	-	-	45	101
Research Expenses	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>45</b>	<b>-</b>	<b>-</b>	<b>45</b>	<b>101</b>
<b>A4 Asset and investment purchases, (see table)</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total payments</b>	<b>45</b>	<b>-</b>	<b>-</b>	<b>45</b>	<b>101</b>
<b>Net of receipts/(payments)</b>	<b>310</b>	<b>-</b>	<b>-</b>	<b>310</b>	<b>1,185</b>
<b>A5 Transfers between funds</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>A6 Cash funds last year end</b>	<b>1,185</b>	<b>-</b>	<b>-</b>	<b>1,185</b>	<b>-</b>
<b>Cash funds this year end</b>	<b>1,495</b>	<b>-</b>	<b>-</b>	<b>1,495</b>	<b>1,185</b>

### Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
------------	---------	------------------------------------	----------------------------------	---------------------------------

**B1 Cash funds**

Cash at Bank	1,496	-	-
	-	-	-
	-	-	-
<b>Total cash funds</b>	<b>1,496</b>	<b>-</b>	<b>-</b>

(agree balances with receipts and payments account(s))

Agreement Error

OK

OK

**Unrestricted funds**

**Restricted funds**

**Endowment funds**

to nearest £

to nearest £

to nearest £

**Details**

**B2 Other monetary assets**

	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-

**Details**

**B3 Investment assets**

Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
		-	-
		-	-
		-	-
		-	-
		-	-

**Details**

**B4 Assets retained for the charity's own use**

Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-

**Details**

**B5 Liabilities**

Details	Fund to which liability relates	Amount due (optional)	When due (optional)
		-	
		-	
		-	
		-	
		-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval

**VITILIGO SUPPORT UK**

England & Wales - Charity number 1170557

---

# Accounts

---



## Trustees' Annual Report for the period

From 02/04/2022 Period start date To 01/04/2023  
Period end date

Charity name: Vitiligo Support UK

Charity registration number: 1170557

## Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To promote and protect the physical and mental health of sufferers of vitiligo in England and Wales by the provision of support, education and practical advice and to advance the education of the public in all areas relating to vitiligo
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	Providing advice, advocacy, support, and information to those with vitiligo, their families and friends via our closed support group on Facebook Using social media to signpost services and information. Providing advocacy for patients with vitiligo via membership of committees and working groups within the British Association of Dermatologists (BAD) Leading as patient representative on the Patient Engagement Workstream at the BAD and providing a survey of patients' views on the increase in teledermatology in this period. Leading a patient representative on the development of an app to provide psychosocial support for patients with skin disease in conjunction with Professor Andrew Thompson of the University of Cardiff and Dr Anthony Bewley, consultant dermatologist and chair Psychodermatology UK.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	We have had regard to the guidance issued by the Charity Commission in respect of public benefit.

### Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
--	----------------	--

Policy on grant making	Para 1.38	
Policy on social investment including program related investment	Para 1.38	
Contribution made by volunteers	Para 1.38	
Other		

## Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p>As a charity, we have provided extensive support to our membership in navigating access to dermatology. Waiting lists in dermatology continue to be extremely long, and we are concerned that vitiligo patients are triaged out of secondary care in favour of other inflammatory skin conditions. We provided patients with a guide to talking to your GP about your vitiligo based on the information provided by the Primary Care Dermatology Society.</p> <p>We became part of the Education Subcommittee at the BAD in this period and began work on a psychodermatology project alongside Professor Andrew Thompson of Cardiff University. The aim of this is to provide online content to support patients who are significantly impacted by their skin condition. This is in the absence of any national psychodermatology service for patients.</p> <p>We continued to provide extensive support and advice to patients in our closed Facebook group and used the BAD Guidelines for managing patients with vitiligo to provide standardised advice for our members to enable them to access primary care, shape their treatment and go on to secondary care where appropriate.</p>

### Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

## Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	The charity maintained its stable financial position in this period.
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	No material reserves are held due to the charity's conservative management.
Amount of reserves held	Para 1.22	See above.
Reasons for holding zero reserves	Para 1.22	See above.
Details of fund materially in deficit	Para 1.24	See above.
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	None.

### Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	
Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	
Other		

## Structure, Governance and Management

Description of charity's trusts:		
Type of governing document (trust deed, royal charter)	Para 1.25	CIO Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	Charitable Incorporated Organisation
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Trustees are appointed by the existing trustees, following the provisions of the constitution.

### Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

### Reference and Administrative details

Charity name	Vitiligo Support UK
Other name the charity uses	
Registered charity number	1170557
Charity's principal address	36 Avondale Avenue, Esher, Surrey KT10 0DA

**Names of the charity trustees who manage the charity**

	<b>Trustee name</b>	<b>Office (if any)</b>	<b>Dates acted if not for whole year</b>	<b>Name of person (or body) entitled to appoint trustee (if any)</b>
1	Emma Rush	Chair of Trustees		
2	Peter Rush			
3	Kate Burnside			
4	Sara Day			
5	Joanna Jackson			
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

**Corporate trustees – names of the directors at the date the report was approved**

<b>Director name</b>		

**Name of trustees holding title to property belonging to the charity**

<b>Trustee name</b>	<b>Dates acted if not for whole year</b>	

## Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	

### Additional information (optional)

#### Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

#### Name of chief executive or names of senior staff members (Optional information)

--

## Exemptions from disclosure

Reason for non-disclosure of key personnel details

None
------

## Other optional information

--

## Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)

--	--

Full name(s)

--	--

Position (eg Secretary,  
Chair, etc)

--	--

Date

--



## Receipts and payments accounts

CC16a

For the period from	3-Apr-22	To	2-Apr-23
---------------------	----------	----	----------

### Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
<b>A1 Receipts</b>	-				
Donations	1,084	-	-	1,084	84
Grant	-	-	-	-	-
Interest Received	202	-	-	202	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total(Gross income for AR)</b>	<b>1,286</b>	<b>-</b>	<b>-</b>	<b>1,286</b>	<b>84</b>
<b>A2 Asset and investment sales, (see table).</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total receipts</b>	<b>1,286</b>	<b>-</b>	<b>-</b>	<b>1,286</b>	<b>84</b>
<b>A3 Payments</b>					
Insurance	101	-	-	101	-
Research Expenses	-	-	-	-	84
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>101</b>	<b>-</b>	<b>-</b>	<b>101</b>	<b>84</b>
<b>A4 Asset and investment purchases, (see table)</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total payments</b>	<b>101</b>	<b>-</b>	<b>-</b>	<b>101</b>	<b>84</b>
<b>Net of receipts/(payments)</b>	<b>1,185</b>	<b>-</b>	<b>-</b>	<b>1,185</b>	<b>-</b>
<b>A5 Transfers between funds</b>	-	-	-	-	-
<b>A6 Cash funds last year end</b>	-	-	-	-	-
<b>Cash funds this year end</b>	<b>1,185</b>	<b>-</b>	<b>-</b>	<b>1,185</b>	<b>-</b>

### Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
------------	---------	------------------------------------	----------------------------------	---------------------------------

**B1 Cash funds**

Cash at Bank	1,185	-	-
	-	-	-
	-	-	-
<b>Total cash funds</b>	<b>1,185</b>	<b>-</b>	<b>-</b>

(agree balances with receipts and payments account(s))

OK	OK	OK
<b>Unrestricted funds</b>	<b>Restricted funds</b>	<b>Endowment funds</b>
to nearest £	to nearest £	to nearest £

**B2 Other monetary assets**

Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-

**B3 Investment assets**

Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
		-	-
		-	-
		-	-
		-	-
		-	-

**B4 Assets retained for the charity's own use**

Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-

**B5 Liabilities**

Details	Fund to which liability relates	Amount due (optional)	When due (optional)
		-	
		-	
		-	
		-	
		-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval

**VITILIGO SUPPORT UK**

England & Wales - Charity number 1170557

---

# Accounts

---



## Trustees' Annual Report for the period

From **02/04/2021** Period start date To **01/04/2022**  
Period end date

**Charity name: Vitiligo Support UK**

**Charity registration number: 1170557**

## Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To promote and protect the physical and mental health of sufferers of vitiligo in England and Wales by the provision of support, education and practical advice and to advance the education of the public in all areas relating to vitiligo
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	Providing advice, advocacy, support, and information to those with vitiligo, their families and friends via our closed support group on Facebook Using social media to signpost services and information. Providing advocacy for patients with vitiligo via membership of committees and working groups within the British Association of Dermatologists (BAD) Leading as patient representative on the Patient Engagement Workstream at the BAD and providing a survey of patients' views on the increase in teledermatology in this period. Leading a patient representative on the development of an app to provide psychosocial support for patients with skin disease in conjunction with Professor Andrew Thompson of the University of Cardiff and Dr Anthony Bewley, consultant dermatologist and chair Psychodermatology UK.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	We have had regard to the guidance issued by the Charity Commission in respect of public benefit.

### Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
--	----------------	--

Policy on grant making	Para 1.38	
Policy on social investment including program related investment	Para 1.38	
Contribution made by volunteers	Para 1.38	
Other		

## Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p>As a charity, we have continued to work to ensure that vitiligo is represented nationally as a condition at the British Association of Dermatologists (BAD) and in the NHS Working Group relating to the management of teledermatology.</p> <p>We contributed as lay representative to production of the national NB-UVB guidelines, written by the working group at the BAD&gt;</p> <p>We lead the Patient Engagement Workstream at the BAD in this period and produced a survey of patients eliciting views on the increased use of teledermatology and its impact on the psychosocial aspects of skin disease and medication compliance, the results of which were published as a letter in the British Journal of Dermatology.</p> <p>We provided extensive support and advice to patients in our closed Facebook group and used the Guidelines for managing patients with vitiligo to provide standardised advice for our members to enable them to access primary care, shape their treatment and go on to secondary care where appropriate.</p> <p>We increased our presence on Twitter, using our account to disseminate advice on vitiligo and attendant conditions such as thyroid disease.</p>

		We provided advice and support to Dr John Ferguson of Guy's Hospital in the establishment of a specialist Vitiligo clinic and application for funding for a data registry relating to vitiligo.
--	--	---

**Additional information (optional)**

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

## Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	The charity maintained its stable financial position in this period.
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	No material reserves are held due to the charity's conservative management.
Amount of reserves held	Para 1.22	See above.
Reasons for holding zero reserves	Para 1.22	See above.
Details of fund materially in deficit	Para 1.24	See above.
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	None.

### Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	
Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	
Other		

## Structure, Governance and Management

Description of charity's trusts:		
Type of governing document (trust deed, royal charter)	Para 1.25	CIO Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	Charitable Incorporated Organisation
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Trustees are appointed by the existing trustees, following the provisions of the constitution.

### Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

### Reference and Administrative details

Charity name	Vitiligo Support UK
Other name the charity uses	
Registered charity number	1170557
Charity's principal address	36 Avondale Avenue, Esher, Surrey KT10 0DA

**Names of the charity trustees who manage the charity**

	<b>Trustee name</b>	<b>Office (if any)</b>	<b>Dates acted if not for whole year</b>	<b>Name of person (or body) entitled to appoint trustee (if any)</b>
1	Emma Rush	Chair of Trustees		
2	Peter Rush			
3	Kate Burnside			
4	Sara Day			
5	Joanna Jackson			
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

**Corporate trustees – names of the directors at the date the report was approved**

<b>Director name</b>		

**Name of trustees holding title to property belonging to the charity**

<b>Trustee name</b>	<b>Dates acted if not for whole year</b>	

## Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	

### Additional information (optional)

#### Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
-----------------	------	---------


#### Name of chief executive or names of senior staff members (Optional information)

--

## Exemptions from disclosure

Reason for non-disclosure of key personnel details

None
------

## Other optional information

--

## Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

<b>Signature(s)</b>		
<b>Full name(s)</b>		
<b>Position (eg Secretary, Chair, etc)</b>		
<b>Date</b>		



## Receipts and payments accounts

CC16a

For the period from	2-Apr-21	To	1-Apr-22
---------------------	----------	----	----------

### Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
<b>A1 Receipts</b>	-				
Donations	84	-	-	84	-
Grant	-	-	-	-	84
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b> (Gross income for AR)	84	-	-	84	84
<b>A2 Asset and investment sales, (see table).</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	-	-	-	-	-
<b>Total receipts</b>	84	-	-	84	84
<b>A3 Payments</b>					
Insurance	84	-	-	84	-
Research Expenses	-	-	-	-	84
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	84	-	-	84	84
<b>A4 Asset and investment purchases, (see table)</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	-	-	-	-	-
<b>Total payments</b>	84	-	-	84	84
<b>Net of receipts/(payments)</b>	-	-	-	-	-
<b>A5 Transfers between funds</b>	-	-	-	-	-
<b>A6 Cash funds last year end</b>	-	-	-	-	-
<b>Cash funds this year end</b>	-	-	-	-	-

### Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
<b>B1 Cash funds</b>		-	-	-
		-	-	-
		-	-	-
		-	-	-
	<b>Total cash funds</b>	-	-	-
	(agree balances with receipts and payments account(s))	OK	OK	OK
		<b>Unrestricted funds</b>	<b>Restricted funds</b>	<b>Endowment funds</b>

	Details	to nearest £	to nearest £	to nearest £
<b>B2 Other monetary assets</b>		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
<b>B3 Investment assets</b>			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
<b>B4 Assets retained for the charity's own use</b>			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
<b>B5 Liabilities</b>			-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval

**VITILIGO SUPPORT UK**

England & Wales - Charity number 1170557

---

# Accounts

---



## Trustees' Annual Report for the period

From **02/04/2020** Period start date To **01/04/2021**  
Period end date

Charity name: **Vitiligo Support UK**

Charity registration number: **1170557**

## Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To promote and protect the physical and mental health of sufferers of vitiligo in England and Wales by the provision of support, education and practical advice and to advance the education of the public in all areas relating to vitiligo
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	<p>This period was spent in part in national lockdown due to COVID-19.</p> <p>We provided support to patients through our support group who were experiencing heightened distress at their skin condition during this period.</p> <p>We represented patients with vitiligo in the NHS Dermatology Advisory Group in dealing with the advent of teledermatology for patients and representing concerns that this might disadvantage vitiligo patients.</p> <p>We continued to contribute to the British Association of Dermatologists Guidelines for managing patients with vitiligo representing the practicalities of having the skin disease, and the psychosocial impact of the disease and providing a vital treatment roadmap giving structure and support to patients' treatment journeys.</p> <p>We responded to patient queries through our main engagement with our members, the Facebook group, giving advice as to how to access treatment using the Guidelines mentioned above and supporting people in their advocacy for their skin disease.</p>
Statement confirming whether the trustees have had regard to the guidance	Para 1.18	We have had regard to the guidance issued by the Charity Commission in respect of public benefit.

issued by the Charity Commission on public benefit		
--	--	--

### Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	
Policy on social investment including program related investment	Para 1.38	
Contribution made by volunteers	Para 1.38	
Other		

### Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p>As a charity, we have worked hard to ensure that vitiligo is represented as a condition at the British Association of Dermatologists (BAD) and in the NHS Working Group relating to the management of teledermatology.</p> <p>We advocate for patients by representing them on committees such as the Patient Engagement Workstream at the BAD where we ensure that we can canvass the views of our members on issues that arise in relation to current topics, such as the use of images to triage patients into the dermatology service.</p> <p>We contributed to the "Vitiligo" chapter of the book <i>Skin conditions in young people: A practical guide on how to be comfortable in your skin</i> by Tess McPherson in order to help young people with vitiligo and educate them about treatments for their condition and managing its impact.</p> <p>Our work on the Guidelines for managing patients with vitiligo enabled us in particular to represent the importance of including psychosocial impact as an assessment</p>

		criteria for access to secondary care, as we have first hand experience through our membership in this being one of the key impacts of the skin disease.
--	--	--

**Additional information (optional)**

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

## Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	The charity maintained its stable financial position in this period.
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	No material reserves are held due to the charity's conservative management.
Amount of reserves held	Para 1.22	See above.
Reasons for holding zero reserves	Para 1.22	See above.
Details of fund materially in deficit	Para 1.24	See above.
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	None.

### Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	
Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	
Other		

## Structure, Governance and Management

Description of charity's trusts:		
Type of governing document (trust deed, royal charter)	Para 1.25	CIO Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	Charitable Incorporated Organisation
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Trustees are appointed by the existing trustees, following the provisions of the constitution.

### Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

### Reference and Administrative details

Charity name	Vitiligo Support UK
Other name the charity uses	
Registered charity number	1170557
Charity's principal address	36 Avondale Avenue, Esher, Surrey KT10 0DA

**Names of the charity trustees who manage the charity**

	<b>Trustee name</b>	<b>Office (if any)</b>	<b>Dates acted if not for whole year</b>	<b>Name of person (or body) entitled to appoint trustee (if any)</b>
1	Emma Rush	Chair of Trustees		
2	Peter Rush			
3	Kate Burnside			
4	Sara Day			
5	Joanna Jackson			
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

**Corporate trustees – names of the directors at the date the report was approved**

<b>Director name</b>		

**Name of trustees holding title to property belonging to the charity**

<b>Trustee name</b>	<b>Dates acted if not for whole year</b>	

## Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	

### Additional information (optional)

#### Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
-----------------	------	---------


#### Name of chief executive or names of senior staff members (Optional information)

--

## Exemptions from disclosure

Reason for non-disclosure of key personnel details

None
------

## Other optional information

--

## Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

<b>Signature(s)</b>		
<b>Full name(s)</b>		
<b>Position (eg Secretary, Chair, etc)</b>		
<b>Date</b>		



**Receipts and payments accounts**

For the period from	01-May-20	To	30-Apr-21
---------------------	-----------	----	-----------

**Section A Receipts and payments**

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
<b>A1 Receipts</b>					
Donations	84	-	-	84	-
Grant	-	-	-	-	23,597
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total (Gross income for AR)</b>	<b>84</b>	<b>-</b>	<b>-</b>	<b>84</b>	<b>23,597</b>
<b>A2 Asset and investment sales, (see table).</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total receipts</b>	<b>84</b>	<b>-</b>	<b>-</b>	<b>84</b>	<b>23,597</b>
<b>A3 Payments</b>					
Insurance	84	-	-	84	-
Research Expenses	-	-	-	-	23,597
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>84</b>	<b>-</b>	<b>-</b>	<b>84</b>	<b>23,597</b>
<b>A4 Asset and investment purchases, (see table)</b>					
	-	-	-	-	-
	-	-	-	-	-
<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total payments</b>	<b>84</b>	<b>-</b>	<b>-</b>	<b>84</b>	<b>23,597</b>
<b>Net of receipts/(payments)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	-	-	-	-	-
<b>Cash funds this year end</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

**Section B Statement of assets and liabilities at the end of the period**

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
<b>B1 Cash funds</b>				
CCXX R1 accounts (SS)	1	-	-	-
		-	-	09/04/2023 -

	-	-	-
<b>Total cash funds</b>	-	-	-
(agree balances with receipts and payments account(s))	OK	OK	OK

	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
<b>B2 Other monetary assets</b>			
Details			
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-

	Fund to which asset belongs	Cost (optional)	Current value (optional)
<b>B3 Investment assets</b>		-	-
Details		-	-
		-	-
		-	-
		-	-
		-	-
		-	-

	Fund to which asset belongs	Cost (optional)	Current value (optional)
<b>B4 Assets retained for the charity's own use</b>		-	-
Details		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-

	Fund to which liability relates	Amount due (optional)	When due (optional)
<b>B5 Liabilities</b>		-	
Details		-	
		-	
		-	
		-	
		-	
		-	

Signed by one or two trustees on behalf of all the trustees	Signature	Print Name	Date of approval